The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 March 2026•

1 min read

NEJM Publishes Positive Phase 3 Results for Priovant’s Brepocitinib in Dermatomyositis

Key Facts

1Priovant Therapeutics published positive Phase 3 VALOR trial results for brepocitinib in the New England Journal of Medicine (NEJM).

Version History

2 additional sources confirmed this story

Priovant Therapeutics has announced the formal publication of positive Phase 3 VALOR trial results for brepocitinib in the New England Journal of Medicine (NEJM). The study evaluated the efficacy and safety of the drug in adults suffering from dermatomyositis (DM), a rare and debilitating autoimmune disease. The publication in such a prestigious medical journal provides high-level clinical validation, which is a critical milestone for future regulatory approval and market adoption. For partners Roivant Sciences (ROIV) and Pfizer (PFE), this development serves as a significant de-risking event in their biotechnology portfolios. Clinical data indicated substantial improvement in patient outcomes, positioning brepocitinib as a potential leading treatment for this underserved patient population. Market analysts view this formal validation as a positive catalyst for the long-term commercial viability of the therapy.